HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now

Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20-25% of all breast cancers. Multiple HER2targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) Lapatinib, neratinib, tucatinib, and pyrotinib. These drugs target HER2 and other receptors of the epidermal growth factor receptor family, therefore each has unique efficacy and adverse event profile. HER2-directed TKIs have been studied in the early stage and advanced settings and have shown promising responses. There is increasing interest in utilizing these drugs in combination with chemotherapy and /or other HER2-directed agents in patients with central nervous system involvement, TKIs have shown to be effective in this setting for which treatment options have been previously limited and the prognosis remains poor. The aim of this review is to summarize currently approved TKIs for HER2+ breast, key clinical trials, and their use in current clinical practice.

Automated summary

HER2-positive breast cancer accounts for a significant proportion of cases, with several targeted therapies available including TKIs which have shown promising responses in both early and advanced settings. In patients with central nervous system involvement, TKIs have shown efficacy, which is important for those with limited treatment options and poor prognosis in this setting.